Table 2 The information of the pediatric patients of HSCT-2.
No | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
Internal of the two transplantations(days) | 370 | 20 | 19 | 36 | 82 | 170 | 51 | 46 | 47 | 1000 |
Whether to change the donor | Yes | Yes | Yes | No | Yes | No | Yes | Yes | No | Yes |
CMV of pre-transplantation | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
Donor | MSD | Haploidentical family donor | Haploidentical family donor | Haploidentical family donor | MUD | MSD | Haploidentical family donor | Haploidentical family donor | Haploidentical family donor | MUD |
Conditioning regimen | CTX + ATG | TBI + FLU + CTX + ALG + BU | TBI + FLU + CTX + ALG + BU | TBI + FLU + CTX | TBI + BU + CTX + ALG | TBI + FLU + CTX | TBI + FLU + CTX + ALG + Mel | TBI + FLU + CTX + ATG | TBI + FLU + CTX + ATG | FLU + CTX + ATG |
Graft resource | UC | BM + PBSC | BM + PBSC | PBSC | PBSC | PBSC | PBSC + UC | BM + PBSC + UC | BM + PBSC + UC | PBSC |
The dose of MNCs (*106) and CD34+ (*106) cells | Unknown | PBSC:MNC:10.35 CD34+ :6.29 BM: MNC:3.18 CD34+ :0.83 | PBSC: MNC:11.17 CD34+ :5.8 BM: MNC:4.38 CD34+ :2.89 | MNC:13.37 CD34+ :5.27 | MNC:12.8 CD34+ :8 | MNC:8.8 CD34+ :2.45 | MNC:6.8 CD34+ :5.27 | PBSC: MNC:9.38 CD34+ :7.23 BM: MNC:3.5 CD34+ :1.3 | PBSC: MNC:8.3 CD34+ :6.5 BM: MNC:3.6 CD34+ :1.8 | MNC:10.4 CD34+ :5.6 |
Time of neutrophil engraftment | 18 | 13 | 11 | 12 | 12 | 10 | 13 | 16 | 17 | 12 |
Time of platelet engraftment | 14 | 26 | 17 | 14 | 20 | 19 | 52 | 25 | ||
Medicine of anti-GVHD | A low dose of PT-CY + CsA + MMF + MTX | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF + MTX | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF | A low dose of PT-CY + CsA + MMF + MTX |
GVHD | Acute skin GVHD | Chronic liver GVHD | Acute intestine GVHD | Acute intestine GVHD | Acute skin and intestine GVHD | Acute skin and intestine GVHD | ||||
CMV post-transplantation | Negative | Positive | Positive | Negative | Positive | Negative | Negative | Negative | Negative | Negative |
Time of disease-free survival (days) | 160 | 1000 | 1002 | 130 | 1011 | 98 | 128 | 1752 | 1753 | 191 |
Outcomes | The chimerism was completely donor type at one month, but the patient died of lung infection 5 months after HSCT-2 | The chimerism was completely donor type at 32 months | The chimerism was completely donor type at 19 months | The chimerism was completely donor type at 5 months | The chimerism was completely donor type at 12 months | The chimerism rate was 94.86% | The chimerism was completely donor type at 2 months | The chimerism was completely donor type at 58 months | The chimerism was completely donor type at 58 months | The chimerism was completely donor type at 5 months |
